> top > docs > PMC:7170415 > spans > 8440-10260 > annotations

PMC:7170415 / 8440-10260 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
144 109-119 Species denotes SARS–CoV-2 Tax:2697049
145 267-274 Species denotes persons Tax:9606
146 1595-1602 Species denotes persons Tax:9606
147 300-308 Disease denotes COVID-19 MESH:C000657245
148 505-514 Disease denotes infection MESH:D007239
149 1646-1656 Disease denotes infections MESH:D007239

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T41 109-113 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T42 300-308 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T43 505-514 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T44 1646-1656 Disease denotes infections http://purl.obolibrary.org/obo/MONDO_0005550

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T66 60-65 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T67 118-124 http://purl.obolibrary.org/obo/CLO_0001196 denotes 2 (25)
T68 253-260 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T69 387-388 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T70 389-393 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T71 422-426 http://purl.obolibrary.org/obo/UBERON_0000473 denotes Test
T72 492-496 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T73 537-542 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T74 592-596 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T75 642-647 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T76 705-706 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T77 742-749 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T78 802-806 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T79 944-948 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T80 1028-1033 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T81 1062-1067 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T82 1150-1155 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tests
T83 1177-1178 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T84 1349-1350 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T85 1351-1355 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T86 1481-1482 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T87 1493-1497 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test
T88 1535-1536 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T89 1609-1615 http://purl.obolibrary.org/obo/UBERON_0000473 denotes tested
T90 1704-1707 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T91 1718-1719 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T92 1782-1786 http://purl.obolibrary.org/obo/UBERON_0000473 denotes test

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T64 0-194 Sentence denotes Despite the remarkable speed with which accurate diagnostic tests have been developed and made available for SARS–CoV-2 (25), current tools only partially meet several clinically relevant needs.
T65 195-309 Sentence denotes Figure 1 illustrates different indications for diagnostic testing among persons with proven or suspected COVID-19.
T66 310-421 Sentence denotes For each of these, the most important consideration is the clinical decision a test result will help to inform.
T67 422-889 Sentence denotes Test designs must account for several parameters, such as whether the test detects infection directly (such as the virus itself) or indirectly (such as host antibodies), test turnaround time, the ability to perform many tests at the same time (that is, throughput), the need to have a minimum number of specimens before testing (that is, batching), and the ability to perform the test in low-infrastructure settings (such as on cruise ships or in remote communities).
T68 890-960 Sentence denotes The potential for use at the point of care depends on test complexity.
T69 961-969 Sentence denotes The U.S.
T70 970-1054 Sentence denotes Food and Drug Administration (FDA) categorizes diagnostic tests by their complexity:
T71 1055-1190 Sentence denotes Waived tests are available for use at the point of care, whereas moderate- and high-complexity tests must be performed in a laboratory.
T72 1191-1267 Sentence denotes The intended use also determines which specimen types are ideal or feasible.
T73 1268-1387 Sentence denotes Finally, it is important to recognize that the acceptable diagnostic accuracy of a test may vary according to use case.
T74 1388-1657 Sentence denotes For example, sensitivity and specificity requirements of an assay used to confirm results of a screening test need not be as stringent as those of a method used for standalone diagnosis, because the pool of persons being tested is already enriched with true infections.
T75 1658-1820 Sentence denotes The Foundation for Innovative New Diagnostics has published a detailed assessment of priority use cases to be considered by test developers and policymakers (26).